Risk factors for serotype 19A carriage after introduction of 7-valent pneumococcal vaccination.
Robert Cohen, Corinne Levy, Eric Bonnet...
https://pubmed.ncbi.nlm.nih.gov/21501471/Actively Recruiting
Led by Association Clinique Thérapeutique Infantile du val de Marne · Updated on 2026-10-27
29360
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating the nasopharyngeal carriage of Streptococcus pneumoniae in children, focusing on those with acute otitis media AOM and healthy children. This study aims to understand if the use of pneumococcal conjugate vaccines PCVs has changed the types of bacterial strains present and their resistance to antibiotics. The study includes children from 4 months to 15 years, with a special focus on those with AOM aged 4 to 36 months. Participants include about 2100 children with AOM and 1500 healthy controls. Mandatory nasopharyngeal swabs are collected to analyze bacterial colonization. Optional samples include stool or anorectal swabs from a subgroup of children with AOM aged 6 to 24 months to assess antibiotic resistance of E. coli, and additional nasal swabs to study the presence of respiratory viruses and their association with bacterial strains. Throughout the study, children are evaluated at inclusion for pneumococcal colonization, resistance to penicillin, and emergence of new bacterial serotypes. Researchers also assess the relationship between respiratory viruses and pneumococcal types. The study involves annual enrollment from October to June and includes bacteriological analyses conducted by a national reference center. The total study duration extends to 2029, with ongoing monitoring of bacterial carriage and resistance patterns.
CONDITIONS
Nasopharyngeal Carriage of S. Pneumoniae
C
Corinne Levy, MD
S
Stéphane Béchet, MsC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Association Clinique Thérapeutique Infantile du val de Marne
Lead Sponsor
Pfizer
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Annual enrollment from October to June each year
Participants undergo mandatory nasopharyngeal swabs. Some provide optional stool, anorectal, or nasal swabs to assess bacterial colonization, antibiotic resistance, and respiratory viruses.
One or more visits during the enrollment period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Robert Cohen, Corinne Levy, Eric Bonnet...
https://pubmed.ncbi.nlm.nih.gov/21501471/Robert Cohen, Philippe Bidet, Emmanuelle Varon...
https://pubmed.ncbi.nlm.nih.gov/37196808/Assaf Mizrahi, Robert Cohen, Emmanuelle Varon...
https://pubmed.ncbi.nlm.nih.gov/25037572/André Birgy, Fouad Madhi, Camille Jung...
https://pubmed.ncbi.nlm.nih.gov/31617912/Naim Ouldali, Robert Cohen, Corinne Levy...
https://pubmed.ncbi.nlm.nih.gov/31280295/Alexis Rybak, Corinne Levy, Naïm Ouldali...
https://pubmed.ncbi.nlm.nih.gov/37370339/Corinne Levy, François Vie le Sage, Emmanuelle Varon...
https://pubmed.ncbi.nlm.nih.gov/29637893/Robert Cohen, Emmanuelle Varon, Catherine Doit...
https://pubmed.ncbi.nlm.nih.gov/26271823/Alexis Rybak, Corinne Levy, Stéphane Bonacorsi...
https://pubmed.ncbi.nlm.nih.gov/29227464/Robert Cohen, Corinne Levy, Edouard Bingen...
https://pubmed.ncbi.nlm.nih.gov/22330166/Association Clinique Thérapeutique Infantile du val de Marne
Lead Sponsor
Pfizer
Collaborating Sponsor